Researchers conducted a multicenter, observational study of 884 hospitalized adult patients with Staphylococcus aureus bacteremia. They divided patients into three groups based on how long they had Staphylococcus aureus bacteremia:
● Short (one to two days)
● Intermediate (three to six days)
● Prolonged (seven of more days)
Of the 884 patients, 63 percent experienced a short duration of bacteremia; 28 percent experienced an intermediate duration; and 9 percent a prolonged duration.
The study shows the prolonged group had the highest proportion of methicillin-resistant Staphylococcus aureus. Choice of antibiotic therapy did not significantly affect bacteremia duration.
Researchers also found that metastatic complications, length of stay and 30-day mortality worsened as duration of having the bacteremia increased. Each day of bacteremia was associated with relative risk of death of 1.16.
More articles on healthcare quality:
Death of Louisiana nurse attacked by patient ruled a homicide
833 deaths linked to Congo’s Ebola outbreak: 4 updates
10 health systems hiring medical informatics leaders
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
